MDMA (3, 4-methylenedioxy-methamphetamine) is a psychoactive drug that creates feelings of ecstasy and alters perceptions. It is chemically reminiscent of stimulants such as methamphetamine and the hallucinogen mescaline and was first synthesized in the early 20th Century. While academic and pharmacological research into potential therapeutic applications of MDMA antibodies is ongoing, there are currently no commercially-approved uses of MDMA.
The drug is commonly ingested as a tablet, granulated powder, or a liquid for recreational purposes. In the 1980s and ‘90s, MDMA was one of the most widely-consumed drugs, and it has become intrinsically linked to the iconography of the latter decades’ music scenes. The popularity of the drug and the consistencies of its delivery systems have resulted in a gradual degradation of drug purity, with tablets seized by authorities regularly registering varying compositions of dangerous substances such as mephedrone. Preliminary testing equipment is available to detect diluting, excipient, and adulterant materials in drugs of abuse, but they exhibit a distinct lack of accuracy and concentration-dependent precision. It is possible to detect the presence of MDMA in biological samples using an amphetamine lateral flow test, due to cross-reactivity between the drug and its constituent. However, there is a high possibility of registering false positive results when compared to testing samples using synthetic MDMA antibodies.
This blog post will explore the established ways MDMA antibodies are used for research purposes:
Laboratory Applications of MDMA Antibodies
MDMA antibodies are routinely used in lateral flow testing, enzyme-linked immunosorbent assays (ELISA or EIA), and western blot tests. These methodologies can detect the presence and concentration of MDMA derivatives in biological samples such as hair, saliva, or urine.
The MDMA antibody actively targets MDMA particles in an analyte, which may result in a visible chromatic reaction on the immunosorbent component of the test equipment or display distinct reaction dynamics visible through specialized chromatographic techniques.
These methods are regularly employed to discern the chemical makeup of a substance containing MDMA, providing insights into relative drug purity and composition, and data relating to worldwide drug consumption trends. MDMA antibodies are also increasingly used in emerging therapeutic drug research, in which experts are assessing the potential of MDMA as an intermediary drug for psychotherapy in PTSD treatment.
MDMA Antibodies from Pyxis Laboratories
Pyxis Laboratories provides expertise in the development and synthesis of high-purity drug conjugations and monoclonal antibodies for research applications. Our MDMA antibodies have been formatted as proteins in phosphate-buffered saline (PBS), with pre-determined purity levels for specific applications.
We provide a robust range of further drug conjugates, including:
- Alcohol such as, ethyl glucuronide-BSA (EtG-BSA);
- Amphetamines such as, Amphetamine-BSA, Methamphetamine-BSA, methcathinone-BSA, MDPV-BSA, Mephedrone-BSA and Methylphenidate-BSA (Ritalin-BSA);
- Benzodiazepines, such as Oxazepam-BSA and Clonazepam-BSA;
- Cannabinoids such us, delta-8-THC-BSA, delta-9-THC-BSA; and synthetic cannabinoids such as, JWH-018-BSA, ABpinaca-BSA, UR144-BSA;
- Cocaine, such as BZEG-BSA;
- Hallucinogens/Anesthetics such as, Ketamine-BSA and PCP-BSA;
- Nicotinic such as, Cotinine-BSA
- Opioids such as, Buprenorphine-BSA, Fentanyl-BSA, Methadone-BSA, Morphine-BSA, Oxycodone-BSA, Propoxyphene-BSA and others such as Chloramphenicol-BSA, Gabapentin-BSA and N-acetyl glucosamine-BSA (NAG-BSA).